Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clive Holmes

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|October 23, 2015
Common polygenic variation enhances risk prediction for Alzheimer's diseaseValentina Escott-Price, Rebecca Sims, Christian Bannister, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
JAMA Neurology|May 26, 2018
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive ImpairmentDavid A Wolk, Carl Sadowsky, Beth Safirstein, et al.
JAMA Neurology|January 27, 2015
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque densityCraig Curtis, Jose E Gamez, Upinder Singh, et al.
Trials|July 21, 2020
Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, et al.
Plos One|June 30, 2017
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendationsLucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|October 23, 2015
Common polygenic variation enhances risk prediction for Alzheimer's diseaseValentina Escott-Price, Rebecca Sims, Christian Bannister, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
JAMA Neurology|May 26, 2018
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive ImpairmentDavid A Wolk, Carl Sadowsky, Beth Safirstein, et al.
JAMA Neurology|January 27, 2015
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque densityCraig Curtis, Jose E Gamez, Upinder Singh, et al.
Trials|July 21, 2020
Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, et al.
Plos One|June 30, 2017
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendationsLucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, et al.
Pageof 13